Page 2 - Jack Spinks News Today

2022 was a year of transformation and change:reported $412.5 million in total revenue for the year ended December 31, 2022;reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;reported $492.2 million in cash resources as of December 31, 2022, w...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023. Following t...

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of

Operator: Ladies and gentlemen, thank you for standing by. This is conference operator. Welcome to Zymeworks Third Quarter 2022 Results Conference Call and Webcast.

Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC, Dec. 21, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with...

The Tigers hope to close out an undefeated season as the team travels to Lorman to take on the Braves.

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront...